jump to the main content
jump to the bottom of the page

Contenido en español
Contingut en català
Current language Spanish

COLLABORATE El Meu Clínic

Contenido en español
Contingut en català
Current language Spanish

Pere Gascón

gascon@clinic.cat

Featured publications

Safety and efficacy of alternating treatment with EP2006, a filgrastim biosimilar, and reference filgrastim: a phase III, randomised, double-blind clinical study in the prevention of severe neutropenia in patients with breast cancer receiving myelosuppres

Authors:
Blackwell, K.; Gascon, P.; Krendyukov, A.; Gattu, S.; Li, Y.;

Harbeck, N.;.

Reference: ANNALS OF ONCOLOGY.
Fatigue- and health-related quality-of-life in anemic patients with lymphoma or multiple myeloma

Authors:
Gascon, Pere; Arranz, Reyes; Bargay, Joan; Ramos, Fernando;;

Reference: SUPPORTIVE CARE IN CANCER.
MONITOR-GCSF DLBCL subanalysis: Treatment patterns/outcomes with biosimilar filgrastim for chemotherapy-induced/febrile neutropenia prophylaxis

Authors:
Gascon, Pere; Krendyukov, Andriy; Hoebel, Nadja; Aapro, Matti;;

Reference: EUROPEAN JOURNAL OF HAEMATOLOGY.
Safety Profile of Biosimilar Filgrastim (Zarzio/Zarxio): A Combined Analysis of Phase III Studies

Authors:
Harbeck N.; Gascón P.; Krendyukov A.; Hoebel N.; Gattu S.;

Blackwell K..

Reference: ONCOLOGIST.
Histamine receptor 1 inhibition enhances antitumor therapeutic responses through extracellular signal-regulated kinase (ERK) activation in breast cancer

Authors:
Fernández-Nogueira P.; Noguera-Castells A.; Fuster G.; Recalde-Percaz L.; Moragas N.;

(...)

Carbó N.; Almendro V.; Gascón P.; Bragado P.; Mancino M..

Reference: CANCER LETTERS.

Featured Projects

Inflammation and breast cancer: neuronal influence and pro-inflammatory neuropeptides in the tumoral progression through the modulation of the stem cell phenotype.

Funder: INSTITUTE OF HEALTH CARLOS III. FISS PI12/01706

Duration: 01/01/2013
Mechanisms of transactivation of ErbB family members in breast cancer: a role for tachykinins and the neoneurogenesis.

Funder: INSTITUTE OF HEALTH CARLOS III. FISS PI080022

Duration: 01/01/2009
Effect of integrins and neurokinins in cancer development”

Funder: INSTITUTE OF HEALTH CARLOS III. FISS PI041353

Duration: 01/01/2004